Wealthfront’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
$1.28M Buy
33,382
+1,564
+5% +$54.6K 0.01% 204
2018
Q2
$1.04M Buy
31,818
+3,033
+11% +$91.5K 0.01% 243
2018
Q1
$786K Buy
28,785
+2,083
+8% +$56.6K 0.01% 302
2017
Q4
$662K Sell
26,702
-1,254
-4% -$34.6K 0.01% 298
2017
Q3
$815K Sell
27,956
-700
-2% -$19.3K 0.01% 231
2017
Q2
$794K Buy
28,656
+1,949
+7% +$51.7K 0.01% 185
2017
Q1
$664K Buy
26,707
+2,979
+13% +$72.4K 0.01% 178
2016
Q4
$513K Buy
23,728
+1,513
+7% +$33K 0.01% 196
2016
Q3
$529K Buy
22,215
+1,484
+7% +$35.4K 0.01% 173
2016
Q2
$484K Buy
20,731
+2,254
+12% +$48.8K 0.01% 176
2016
Q1
$348K Sell
18,477
-3,117
-14% -$54.8K 0.01% 217
2015
Q4
$398K Buy
21,594
+6,905
+47% +$124K 0.01% 172
2015
Q3
$241K Buy
14,689
+3,975
+37% +$67.9K 0.01% 240
2015
Q2
$190K Buy
10,714
+2,098
+24% +$37.5K 0.01% 275
2015
Q1
$153K Buy
8,616
+2,289
+36% +$36.2K 0.01% 302
2014
Q4
$84K Buy
6,327
+5,010
+380% +$64K ﹤0.01% 387
2014
Q3
$16K Sell
1,317
-1,950
-60% -$24.6K ﹤0.01% 513
2014
Q2
$43K Buy
3,267
+375
+13% +$4.88K ﹤0.01% 394
2014
Q1
$39K Buy
+2,892
New +$38K ﹤0.01% 318

Other funds holding BSX

Wealthfront's BSX Position: Q3 2018 in Review

Wealthfront increased its Boston Scientific (BSX) stake by 4.9% in Q3 2018, buying an estimated $54.6K and bringing the position to 33,382 shares worth $1.28M. The position accounts for 0.01% of the portfolio, ranked #204.

Wealthfront first reported a position in BSX in Q1 2014 and has held it in 19 quarters since. 699 funds tracked by Wall St. Rank hold BSX as of Q3 2018.

  • Wealthfront held 33,382 shares of Boston Scientific worth $1.28M as of Q3 2018.
  • Wealthfront bought 1,564 Boston Scientific shares in Q3 2018, an estimated $54.6K.
  • Boston Scientific made up 0.01% of Wealthfront's portfolio in Q3 2018, its #204 holding.
  • Wealthfront first reported a position in Boston Scientific in Q1 2014 and has held it in 19 quarters since.
  • 699 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2018.

Based on Wealthfront's 13F filing for Q3 2018, filed 13 Nov 2018.